PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34848831-5	2021	B7-H3 in TCs and B7-H4 and VISTA in ICs were observed in 58.1%, 46.6%, and 83.1% of PD-L1-negative samples, respectively.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	9-12	CD276 molecule	Homo sapiens	0-5	
34848831-7	2021	VISTA (in ICs) and B7-H4 were more frequent in primary tumors than in recurrent counterparts and correlated with improved survival; in contrast, B7-H3 positivity in TCs was less frequent in primary tumors and correlated with short disease-specific survival.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	165-168	CD276 molecule	Homo sapiens	145-150	
34326649-5	2021	B7-H3 expression in TCs was more frequent in squamous cell carcinoma, PD-L1-positive samples, and tissues from patients with lymph node metastasis; moreover, its expression was an independent predictor of shorter survival.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	20-23	CD276 molecule	Homo sapiens	0-5	
34326649-6	2021	Conclusion: B7-H3 positivity in TCs is a promising prognostic biomarker, and targeting B7-H3 alone or in combination with PD-1/PD-L1 may be a potential immunotherapeutic strategy for patients with cervical cancer.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	32-35	CD276 molecule	Homo sapiens	12-17